Biome Australia (ASX:BIO) signed a co-investment agreement with Australia's Food and Beverage Accelerator for a jointly funded intellectual property development program for the company's BMB18 probiotic strain, according to a Wednesday filing with the Australian bourse.
Results of the company's initial in vitro studies on BMB18 showed the strain's functional potential in modulating immune responses, reducing inflammation, reducing oxidative stress, and maintaining intestinal barrier integrity, the filing said.
The agreement is backed by a AU$50 million grant awarded to the Food and Beverage Accelerator under the Australian Government Department of Education Trailblazer Program, per the filing.
Biome Australia shares rose nearly 5% in morning trade Wednesday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。